TheInsulin-like Growth Factor 1 Receptor Pathway in Cancer
IGF2
IGF1
IGF1R
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:00 AM Page 1
IGF1
IGF2
IGF1R
AktRas
Tumor
An Overview: The IGF1R Pathway Is Necessary for NormalGrowth and Tumorigenesis and Represents a Potential Targetfor Anticancer Therapy
Tumorigenesis is a highly complex pathological process often resultingfrom aberrant activation or inhibition of key signaling pathways that playessential roles in normal development.1 One such pathway is the insulin-like growth factor 1 receptor (IGF1R) pathway, which controls cellularproliferation, survival, and metabolism through the binding of the ligandsinsulin-like growth factor (IGF) 1 and IGF2 to the IGF1R and the down-stream activation of the PI3K/Akt and Ras/MAPK signal transduction cascades.1-3 A host of studies have determined that the IGF1R pathway isdysregulated in a variety of human cancers, including pancreatic, colorectal,prostate, breast, ovarian, bladder, kidney, and lung, and circulating levelsof IGF1 correlate with increased cancer risk.1-4 Furthermore, increasedIGF1R signaling contributes to the development of resistance to some anti-cancer agents targeting different signaling pathways that participate inmolecular cross talk with the IGF pathway.2,5 As such, the IGF1R pathwayrepresents a potential target for anticancer therapy.
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:00 AM Page 2
The IGF1R Pathway Is Activated by the Binding of IGF1 or IGF2
IGF1R signaling is predominantly activated by the binding of two structurally
related ligands, IGF1 and IGF2.1,5 IGF1R is a transmembrane receptor tyrosine
kinase (RTK) consisting of two extracellular α-chains and two intracellular
β-chains linked by disulfide bonds to form a tetramer. IGF1R shares 60%
amino acid sequence homology with the insulin receptor (IR) and each
can form homodimers or hybrid heterodimers with the other.1,5 Another
receptor in this family, IGF2R, is structurally and functionally distinct from
IGF1R and IR and has no signaling component associated with it.5 The
ligands IGF1, IGF2, and insulin are capable of binding to homodimeric or
hybrid IGF1R and IR with varying affinities; however, the primary ligands
for IGF1R are IGF1 and IGF2.1,5,6 IGF1 and IGF2 share 62% homology in
amino acid sequence and 40% homology to pro-insulin.1,5,7 IGF1 and IGF2
are produced by multiple tissues, especially the liver, and circulate in the
blood where they exert endocrine as well as autocrine and paracrine effects.7
IGF2R
Internalization
Degradation
IR-A
IR-BIR-A/IGF1R IR-B/IGF1RIGF1R
IGF1
Insulin
IGF2
Reference: Chao W, et al. Cytokine Growth Factor Rev. 2008;19:111-120.
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:00 AM Page 4
IGF1R Signaling Is Modulated by IGF1 and IGF2, ProducedLocally and From Distant Sites
Regulation of IGF1R signaling occurs through multiple steps both systemically
and locally.8 Though IGF1 and IGF2 are produced in many tissues, one
predominant site of IGF production is the liver, where they are secreted in
response to growth hormone (GH).8 After IGFs are secreted, less than 1%
circulate in a free, unbound state; the majority are bound to one of six related
high-affinity IGF binding proteins (IGFBPs).1,7,8 Greater than 90% of circulating
IGFs are bound specifically to IGFBP-3.7 Through binding to IGFs, IGFBPs control
IGF half-life as well as their availability to bind to receptors.8 Dissociation of
IGFs from IGFBPs allows the ligands to bind to IGF1R in a variety of tissues
and also suppresses the production of GH in the pituitary gland as part of a
negative feedback loop.8
IGF1R
IGF1R
GHR
LiverBrain
Pituitary
Gland
1. Growth hormone (GH) producedby the pituitary gland stimulatesIGF production from the liver
2. IGFBPsproduced in the liverbind to IGF
3. In a variety of tissues,IGF dissociates fromIGFBP-3 and binds to IGF1R
4. IGF1R activationresults in adecrease in GHproduction by the pituitarygland
© iStockphoto.com/Jana Blašková GHR = growth hormone receptor.
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:00 AM Page 6
Activation of IGF1R Triggers Intracellular Signaling Cascades
IGF1 or IGF2 ligands that are not bound by IGFBP are free tobind to the extracellular α-chains of the IGF1R, resulting inhomodimerization of the receptor and autophosphorylation of the intracellular juxtamembrane tyrosine kinase domains attyrosine 950, creating docking sites for adaptor proteins such as IRS1 and Shc.1 Phosphorylation and binding of adaptor proteins initiates downstream signaling events that result incell proliferation, survival, and metabolism.2
IGF1IGF2
IRS1Shc
IGF1R
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:00 AM Page 8
IGF1
IGF2
Binding of
IGF1 or IGF2
Cell Survival and
Metabolism PathwayCell Proliferation
Pathway
Shc
Grb2SOSRaf Ras
MEK
IRS1
PI3K
PIP2
PIP3
IGF1R
Akt
ERK
PTEN
IGF1R Signaling Regulates Cell Survival, Metabolic Activity,and Proliferation Through Activation of PI3K/Akt andRas/MAPK Pathways
Activation of the IGF1R pathway and autophosphorylation of the receptorcreates docking sites for the adaptor proteins IRS1 and Shc.1,8,9 IRS1 activatesthe p85 subunit of PI3K, which in turn phosphorylates membrane-boundPIP2 to create PIP3. PIP3 recruits Akt to the membrane where it becomesactivated to regulate cell metabolism, promote cell cycle progression, andinhibit pro-apoptotic signaling by impinging upon downstream targetsincluding mTOR, GSK3-β, BAD, and FOXO.1,9,10 Shc recruits Grb2 and SOSproteins to activate Ras by stimulating GDP exchange for GTP.8 ActivatedRas triggers the classical MAPK pathway, characterized by the sequentialactivation of the kinases Raf, MEK, and ERK. ERK activation leads to transcription of target genes necessary for cell proliferation, such as cyclin D and Myc.8,11
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:00 AM Page 10
IGF1R
Overexpression of IGF1R pathwaycomponents in the tumor
High circulating levels of IGF1or IGFBP-3 are associatedwith an increased risk oftumorigenesis
Tumor
Rationale for Targeting IGF1R in Cancer: IGF1R Signaling IsNecessary for Tumorigenesis
Overexpression of IGF1, IGF2, and/or IGF1R may contribute to tumor
progression in humans.1 IGF1R has been shown to be overexpressed in
a number of human cancers including pancreatic, colorectal, prostate,
breast, ovarian, bladder, and lung.2 IGF1 and IGF2 have also been found
to be expressed at higher than normal levels in cancerous tissues and cell
lines.1,6,12 IGF1 mRNA levels were higher in human cancerous pancreatic
tissue and cell lines compared to normal.12 There is even evidence for
a correlation of increased levels of the binding protein IGFBP-3 (in tumor
tissue or in circulation) with increased tumor growth in some types of
cancers, including breast, prostate, pancreatic, renal cell, and non-small
cell lung cancers.8,13 Furthermore, high levels of IGF1R pathway compo-
nents may be predictive of cancer risk.2 Experimental and clinical studies
have found that elevated plasma concentrations of IGF1 correlates with
increased risk of developing breast, colorectal, prostate, and lung cancers.2
Increased IGF1R signaling contributes to the development of resistance
to some anticancer agents targeting different signaling pathways that
participate in molecular crosstalk with the IGF pathway.2,5,14 Thus, the
IGF1R pathway represents a potential target in the treatment of cancer
worth further investigation.2,5
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:01 AM Page 12
Summary: The IGF1R Pathway in Cancer
The IGF1R pathway plays a central role in cell proliferation, survival (protection
from apoptosis), and the regulation of cellular metabolism.1-3 IGF1R signaling is
necessary for tumorigenesis. Overexpression of IGF1R pathway components is
described in a number of human cancers, such as pancreatic, colorectal, prostate,
breast, ovarian, bladder, kidney, and lung.1,4 Downstream PI3K/Akt and Ras/MAPK
signaling cascades are commonly activated in human cancers by aberrant growth
factor signaling and genetic mutation.10,15 IGF1R signaling contributes to the
development of resistance to various anticancer agents.2,5,14 Thus, the IGF1R
pathway represents a potential therapeutic target in cancer.1,4,14
IGF1
IGF2
Shc
Grb2SOS
RafRas
MEK
IRS1
PI3K
PIP2
PIP3
IGF1R
Akt
ERK
PTEN
Translation
mTOR
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:01 AM Page 14
1. Samani AA, et al. Endocr Rev. 2007;28:20-47.2. Tao Y, et al. Nat Clin Pract Oncol. 2007;4:591-602. 3. Pollak M. Nat Rev Cancer. 2008;8:915-928. 4. Yuen JSP, et al. Expert Opin Ther Targets. 2008;12:589-603. 5. Casa AJ, et al. Front Biosci. 2008;13:3273-3287.6. Chao W, et al. Cytokine Growth Factor Rev. 2008;19:111-120.7. Fürstenberger G, et al. Lancet Oncol. 2002;3:298-302.8. Ryan PD, et al. Oncologist. 2008;13:16-24.9. Kooijman R. Cytokine Growth Factor Rev. 2006;17:305-323.
10. Mitsiades CS. Curr Cancer Drug Targets. 2004;4:235-256.11. Pratilas CA, et al. Clin Cancer Res. 2010;16:3329-3334.12. Bergmann U, et al. Cancer Res. 1995;55:2007-2011.13. Martin JL, et al. J Biol Chem. 2009;284:25542-25552.14. Jones HE, et al. Endocr Relat Cancer. 2006;13:S45-S51.15. McCubrey JA, et al. Biochim Biophys Acta. 2007;1773:
1263-1284.
References Notes
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:01 AM Page 16
Provided as an educational resource. Do not copy or distribute. ©2012 Amgen Inc. All rights reserved. G64823-R1-V1 64825-R2-V1
Current as of February 2012.
Statements in this booklet are based on the company’s current beliefs and Amgen disclaims any duty to update.
For more information about Amgen and its business, including risks and uncertainties,
please refer to Amgen’s filings with the US Securities & Exchange Commission.
AE124711-2 IGF Brochure_No AnnosV19_Layout 1 2/22/2012 11:01 AM Page 20